key: cord-0951140-ryjooo7g authors: Resende, Paola Cristina; Gräf, Tiago; Paixão, Anna Carolina Dias; Appolinario, Luciana; Lopes, Renata Serrano; da Fonseca Mendonça, Ana Carolina; da Rocha, Alice Sampaio Barreto; Motta, Fernando Couto; Neto, Lidio Gonçalves Lima; Khouri, Ricardo; de Oliveira, Camila Indiani; Santos-Muccillo, Pedro; Bezerra, Joao Felipe; Teixeira, Dalane Loudal Florentino; Riediger, Irina; do Carmo Debur, Maria; Ribeiro-Rodrigues, Rodrigo; Leite, Anderson Brandao; do Santos, Cliomar Alves; Gregianini, Tatiana Schäffer; Fernandes, Sandra Bianchini; Bernardes, André Felipe Leal; Cavalcanti, Andrea Cony; Miyajima, Fábio; Sachhi, Claudio; Mattos, Tirza; da Costa, Cristiano Fernandes; Delatorre, Edson; Wallau, Gabriel L; Naveca, Felipe G; Bello, Gonzalo; Siqueira, Marilda Mendonça title: A potential SARS-CoV-2 variant of interest (VOI) harboring mutation E484K in the Spike protein was identified within lineage B.1.1.33 circulating in Brazil date: 2021-03-13 journal: bioRxiv DOI: 10.1101/2021.03.12.434969 sha: b3ffb20ce28b19f2381b0cc9b817f80656d07ec6 doc_id: 951140 cord_uid: ryjooo7g The SARS-CoV-2 epidemic in Brazil was dominated by two lineages designated as B.1.1.28 and B.1.1.33. Two SARS-CoV-2 variants harboring mutations at the receptor-binding domain of the Spike (S) protein, designated as lineages P.1 and P.2, evolved within lineage B.1.1.28 and are rapidly spreading in Brazil. Lineage P.1 is considered a Variant of Concern (VOC) because of the presence of multiple mutations in the S protein (including K417T, E484K, N501Y), while lineage P.2 only harbors mutation S:E484K and is considered a Variant of Interest (VOI). Here we report the identification of a new SARS-CoV-2 VOI within lineage B.1.1.33 that also harbors mutation S:E484K and was detected in Brazil between November 2020 and February 2021. This VOI displayed four non-synonymous lineage-defining mutations (NSP3:A1711V, NSP6:F36L, S:E484K, and NS7b:E33A) and was designated as lineage N.9. The VOI N.9 probably emerged in August 2020 and has spread across different Brazilian states from the Southeast, South, North and Northeast regions. The SARS-CoV-2 epidemic in Brazil was dominated by two lineages designated as B. 1 Table 1 ). Mutational profile was investigated using the nextclade tool Nucleotide Among the 35 genomes identified so far as VOI N.9, 10 Brazilian states were represented, suggesting that this lineage is already highly dispersed in the country. The VOI N. Oswaldo Cruz Institute, Fiocruz 2. Plataforma de Vigilância Molecular Laboratório de Enfermidades Infecciosas Transmitidas por Vetores, Instituto Gonçalo Moniz Laboratório Central de Saúde Pública do Estado do Alagoas Fundação de Vigilância em Saúde do Amazonas Centro de Ciências Exatas Leônidas e Maria Deane Institute, Fiocruz 23. Laboratório de AIDS e Imunologia Molecular Evolution and epidemic spread of SARS-CoV-2 in Brazil Evolutionary dynamics and dissemination pattern of the SARS-CoV-2 lineage B.1.1.33 during the early pandemic phase in Brazil Novel SARS-CoV-2 Variant Identified in Travelers from Brazil to Japan COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1. Research Square Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen) Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10 Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies Comprehensive mapping of mutations in the SARS CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies Increased Resistance of SARS-CoV-2 Variants B.1.351 and B to Antibody Neutralization The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape This study was approved by the FIOCRUZ-IOC Ethics Committee (CAAE: 68118417.6.0000.5248 and 32333120.4.0000.5190) and the Brazilian Ministry of the Environment (MMA) SISGEN (A1767C3).The authors wish to thank all the health care workers and scientists who have worked hard to deal with this pandemic threat, the GISAID team, and all the EpiCoV database's submitters, GISAID acknowledgment table containing sequences used in this study is attached to this post (Appendix Table 2 ). We also appreciate the support of the Fiocruz COVID-19 Genomic Surveillance